News Image

Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock?

By Mill Chart

Last update: Feb 28, 2024

Groth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is suited for growth investing, while it is forming a base and may be ready to breakout. Investors should of course do their own research, but we spotted NEUROCRINE BIOSCIENCES INC showing up in our growth with base formation screen, so it may be worth spending some more time on it.

What does the Growth looks like for NASDAQ:NBIX

ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of NASDAQ:NBIX, the assigned 9 reflects its growth potential:

  • The Earnings Per Share has grown by an impressive 58.17% over the past year.
  • Measured over the past years, NBIX shows a very strong growth in Earnings Per Share. The EPS has been growing by 70.09% on average per year.
  • NBIX shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.76%.
  • The Revenue has been growing by 33.13% on average over the past years. This is a very strong growth!
  • NBIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.64% yearly.
  • NBIX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.87% yearly.

How do we evaluate the Health for NASDAQ:NBIX?

Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:NBIX has achieved a 7 out of 10:

  • NBIX has an Altman-Z score of 9.13. This indicates that NBIX is financially healthy and has little risk of bankruptcy at the moment.
  • NBIX has a better Altman-Z score (9.13) than 82.88% of its industry peers.
  • There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
  • NBIX has a Current Ratio of 2.45. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
  • NBIX has a Quick Ratio of 2.40. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.

Assessing Profitability for NASDAQ:NBIX

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:NBIX, the assigned 9 is noteworthy for profitability:

  • NBIX has a Return On Assets of 7.68%. This is amongst the best in the industry. NBIX outperforms 96.61% of its industry peers.
  • NBIX's Return On Equity of 11.19% is amongst the best of the industry. NBIX outperforms 96.27% of its industry peers.
  • NBIX has a better Return On Invested Capital (11.21%) than 96.78% of its industry peers.
  • The last Return On Invested Capital (11.21%) for NBIX is above the 3 year average (9.89%), which is a sign of increasing profitability.
  • Looking at the Profit Margin, with a value of 13.23%, NBIX belongs to the top of the industry, outperforming 96.61% of the companies in the same industry.
  • In the last couple of years the Profit Margin of NBIX has grown nicely.
  • With an excellent Operating Margin value of 20.92%, NBIX belongs to the best of the industry, outperforming 97.12% of the companies in the same industry.
  • In the last couple of years the Operating Margin of NBIX has grown nicely.
  • With an excellent Gross Margin value of 97.90%, NBIX belongs to the best of the industry, outperforming 97.63% of the companies in the same industry.

How do we evaluate the setup for NASDAQ:NBIX?

Alongside the Technical Rating, ChartMill assigns a Setup Rating to evaluate the consolidation level of a stock. This rating, ranging from 0 to 10, is updated daily and considers various short-term technical indicators. The current setup rating for NASDAQ:NBIX is 8:

NBIX has an excellent technical rating and also presents a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. There is a support zone below the current price at 133.64, a Stop Loss order could be placed below this zone. Very recently a Pocket Pivot signal was observed. This is another positive sign.

Our Strong Growth screener lists more Strong Growth stocks and is updated daily.

Our latest full fundamental report of NBIX contains the most current fundamental analsysis.

Check the latest full technical report of NBIX for a complete technical analysis.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (5/20/2024, 5:52:44 PM)

After market: 141.65 0 (0%)

141.65

-0.64 (-0.45%)

NBIX News

News Image3 days ago - Market News VideoInteresting NBIX Put And Call Options For July 19th
News Image4 days ago - Market News VideoNeurocrine Biosciences Moves Up In Market Cap Rank, Passing Pool
News Image6 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

- CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults - Phase 2 Study for...

News Image11 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present CAHtalyst™ Adult Phase 3 clinical study baseline...

News Image11 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety,...

News Image12 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the...

News Image13 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20...

News Image14 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living with TD...

News Image17 days ago - Investor's Business DailyNvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam

The market rally appears to be picking up steam.

News Image17 days ago - Investor's Business DailyA Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation

Earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation report.

News Image17 days ago - Investor's Business DailyStock Market Rallies On Fed, Jobs Report, Apple: Weekly Review

The Nasdaq regained its 50-day line Friday. The other indexes hit resistance.

News Image17 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for...

NBIX Links
Follow us for more